WallStSmart
CUE

Cue Biopharma

NASDAQ: CUE · HEALTHCARE · BIOTECHNOLOGY

$14.74
+13.38% today

Updated 2026-04-30

Market cap
$57.60M
P/E ratio
P/S ratio
2.10x
EPS (TTM)
$-8.40
Dividend yield
52W range
$5 – $31
Volume
11.4M

Cue Biopharma (CUE) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20152016201720182019202020212022202320242025
Revenue$0.00$0.00$0.00$1.14M$3.46M$3.15M$14.94M$1.25M$5.49M$9.29M$27.47M
Revenue growth (YoY)+202.6%-8.8%+373.7%-91.7%+341.0%+69.2%+195.7%
Cost of revenue$44815.00$202085.00$419568.00$28.54M$27.49M$33.55M$-1.78M$1.81M$38.10M$2.35M$3.48M
Gross profit$-44815.00$-202085.00$-419568.00$-27.40M$3.46M$-30.39M$14.94M$1.25M$-32.61M$9.29M$23.99M
Gross margin-2398.2%100.0%-963.5%100.0%100.0%-593.9%100.0%87.3%
R&D$1.50M$5.69M$18.90M$28.54M$27.49M$33.55M$41.35M$38.58M$40.80M$36.30M$37.74M
SG&A$425081.00$1.97M$4.33M$11.30M$12.74M$14.65M$17.31M$16.17M$16.68M$14.59M$16.24M
Operating income$-1.93M$-7.66M$-23.23M$-38.70M$-36.77M$-45.04M$-43.71M$-53.23M$-52.15M$-41.50M$-26.55M
Operating margin-3386.7%-1063.3%-1428.0%-292.6%-4275.1%-949.9%-446.9%-96.7%
EBITDA$-1.88M$-7.46M$-22.81M$-37.94M$-31.60M$-43.99M$-45.49M$-50.49M$-46.05M$-37.53M$-23.04M
EBITDA margin-3320.2%-913.9%-1394.4%-304.5%-4055.5%-838.8%-404.1%-83.9%
EBIT$-1.93M$-7.66M$-23.23M$-38.70M$-36.77M$-45.04M$-43.71M$-52.30M$-49.49M$-39.88M$-26.52M
Interest expense$0.00$0.00$0.00$0.00$5.65M$463914.00$1.73M$713815.00$1.25M$796000.00$357000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.93M$-7.66M$-23.23M$-38.98M$-36.70M$-44.78M$-44.16M$-53.01M$-50.73M$-40.67M$-26.60M
Net income growth (YoY)-297.1%-203.4%-67.8%+5.9%-22.0%+1.4%-20.0%+4.3%+19.8%+34.6%
Profit margin-3411.5%-1061.2%-1419.8%-295.6%-4257.8%-924.1%-438.0%-96.9%